Pharsight

Relyvrio is owned by Amylyx.

Relyvrio contains Sodium Phenylbutyrate; Taurursodiol.

Relyvrio has a total of 5 drug patents out of which 0 drug patents have expired.

Relyvrio was authorised for market use on 29 September, 2022.

Relyvrio is available in for suspension;oral dosage forms.

Relyvrio can be used as treatment of amyotrophic lateral sclerosis (als) in adults.

Drug patent challenges can be filed against Relyvrio from 2026-09-29.

The generics of Relyvrio are possible to be released after 27 July, 2040.

Application	Filing Date	Opposition Party	Legal Status
EP14775675A	2021-01-12	Lederer & Keller Patentanwälte Partnerschaft mbB	Opposition rejected
EP14775675A	2021-01-11	Bruschettini S.r.l.	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857162	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US10251896	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US9872865	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US11071742	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US11583542	AMYLYX	NA	Jul, 2040 (17 years from now)